 "Strides Arcolab gains on USFDA OKs oral dosage facility at Bangalore")
Strides Arcolab is trading higher by 4% at Rs 933 on BSE in otherwise weak market after the drug maker said that its oral dosage facility (KRS Gardens) at Bangalore has been found acceptable by the United States Food and Drug Administration (US FDA).
The oral dosage facility in Bangalore manufactures oral dosage forms such as tablets, capsules (both hard gelatine and soft gelatine) and sachets. The manufacturing plant supports important current and future submissions for the US Market, Strides Arcolab said in a statement.
The inspection was carried out in August 2014, it added.
The stock opened at Rs 905 and hit a high of Rs 942 on BSE. The trading volumes on the counter almost doubled with a combined 680,449 shares changed hands till 1516 hours on BSE and NSE.
The oral dosage facility in Bangalore manufactures oral dosage forms such as tablets, capsules (both hard gelatine and soft gelatine) and sachets. The manufacturing plant supports important current and future submissions for the US Market, Strides Arcolab said in a statement.
The inspection was carried out in August 2014, it added.
The stock opened at Rs 905 and hit a high of Rs 942 on BSE. The trading volumes on the counter almost doubled with a combined 680,449 shares changed hands till 1516 hours on BSE and NSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%